KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Revenue (2020 - 2025)

Ginkgo Bioworks Holdings' Revenue history spans 6 years, with the latest figure at $33.4 million for Q4 2025.

  • For Q4 2025, Revenue fell 23.84% year-over-year to $33.4 million; the TTM value through Dec 2025 reached $170.2 million, down 25.06%, while the annual FY2025 figure was $170.2 million, 25.06% down from the prior year.
  • Revenue reached $33.4 million in Q4 2025 per DNA's latest filing, down from $38.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $168.4 million in Q1 2022 to a low of $33.4 million in Q4 2025.
  • Average Revenue over 5 years is $72.0 million, with a median of $55.8 million recorded in 2023.
  • Peak YoY movement for Revenue: skyrocketed 483.45% in 2021, then tumbled 64.64% in 2023.
  • A 5-year view of Revenue shows it stood at $148.5 million in 2021, then plummeted by 33.81% to $98.3 million in 2022, then crashed by 64.64% to $34.8 million in 2023, then increased by 26.16% to $43.8 million in 2024, then decreased by 23.84% to $33.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Revenue are $33.4 million (Q4 2025), $38.8 million (Q3 2025), and $49.6 million (Q2 2025).